OakChart

SINTX Technologies Inc

SINTHealthcare·Medical Devices·USA·Nano·NASD·Nov 11 • 11:43 AM ET

1.60+0.05 (3.23%)
2026-11-11 17:48 CET
Market cap
11.72 USD m
Revenue, TTM
3.31 USD m
Net income, TTM
-10.26 USD m
Free cash flow, TTM
-9.25 USD m
EPS diluted, TTM
-2.25
P/E
-
Compare

Price

SINT against its 20, 50 and 200-day averages
2050200beatmissearnings
1.502.002.503.001.9M3.8MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SINTclose 1.6020-day 1.6650-day 1.81200-day 2.151.6052w low

64.1% under the 52-week high of 4.46 on 8 Dec 2025. 52-week low 1.40 on 24 Jul 2026. Last 15 sessions, 28.9% high to low

Profile

SINT
52-week range, 7% of the way up
1.404.46

SINTX Technologies, Inc. is an advanced biomaterials company that develops, manufactures, and commercializes patented and proprietary silicon nitride ceramic biomaterials, composites, devices, and related ceramics technologies for other medical and specialized industrial applications. SINTX has 20 years of experience innovating silicon nitride technologies and operates under a quality management system certified to ISO 13485:2016 and AS9100D, with a product portfolio that includes insulators for Tier 1 aerospace suppliers, the FDA-cleared SiNAPTIC Foot & Ankle Osteotomy Wedge System for reconstructive surgery, OEM manufacturing of FDA-cleared spinal implants, and its SiNERGY technology platform being developed for biocomposite and 3D printing applications. The company was founded by Aaron A. Hofmann and Ashok C. Khandkar in December 1996 and is headquartered in Salt Lake City, UT.

Employees32
IPOFeb 13, 2014
Beta0.57
ATR, 14d0.14
Rel volume0.27
Short float2.12%
Insider own19.80%
Inst own12.73%

Snapshot

6 groups

Valuation

Index-
Market Cap12.10M
Enterprise Value13.10M
Income-10.26M
Sales3.31M
Book/sh0.49
Cash/sh0.26
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees32
IPOFeb 13, 2014

Ratios

P/E-
Forward P/E-
PEG-
P/S3.66
P/B3.25
P/C6.05
P/FCF-
EV/EBITDA-
EV/Sales3.96
Quick Ratio0.99
Current Ratio1.84
Debt/Eq0.88
LT Debt/Eq0.74
Option/ShortNo / Yes

Earnings

EPS (ttm)-2.25
EPS next Y-1.06
EPS next Q-0.34
EPS this Y70.78%
EPS next Y40.93%
EPS next 5Y54.77%
EPS past 3/5Y92.03% 80.47%
Sales past 3/5Y-13.28% 11.38%
EPS Y/Y TTM67.55%
Sales Y/Y TTM160.79%
EPS Q/Q93.09%
Sales Q/Q952.88%
EarningsNov 05 AMC
EPS/Sales Surpr.21.75% 64.25%

Ownership

Insider Own19.80%
Insider Trans0.00%
Inst Own12.73%
Inst Trans30.06%
ROA-92.14%
ROE-250.39%
ROIC-158.28%
Gross Margin54.71%
Oper. Margin-303.38%
Profit Margin-309.87%
SMA20-3.85%
SMA50-11.36%
SMA200-25.67%
Trades-

Technical

Shs Outstand6.89M
Shs Float6.06M
Short Float2.12%
Short Ratio1.11
Short Interest0.13M
52W High4.46 -64.13%
52W Low1.40 14.29%
Volatility9.40% 7.38%
ATR (14)0.14
RSI (14)40.23
Beta0.57
Rel Volume0.27
Avg Volume115.36K
Volume11,814

Performance

Perf Week-3.61%
Perf Month-22.71%
Perf Quarter-6.43%
Perf Half Y-32.77%
Perf YTD-58.55%
Perf Year-56.40%
Perf 3Y-98.04%
Perf 5Y-99.99%
Perf 10Y-100.00%
Recom1.00
Target Price9.25
Prev Close1.55
Price1.60
Change %3.23%

Analyst ratings

latest 2 of 2
DateActionAnalystRating changeTargetImplied
Apr 13, 2026InitiatedHH.C. WainwrightBuy$10+525.0%
Sep 12, 2019InitiatedAAscendiant Capital MarketsBuy

Peers

Mkt cap
TickerCompanyMkt cap
XTNTXtant Medical Holdings Inc38.93M
SIBNSI-BONE Inc1.12B
TNONTenon Medical Inc4.84M
ATECAlphatec Holdings Inc1.16B
OFIXOrthofix Medical Inc291.43M
NMTCNeuroOne Medical Technologies Corp7.29M
BVSBioventus Inc934.10M
GMEDGlobus Medical Inc9.87B
RGNTRegentis Biomaterials Ltd9.09M
CARLCarlsmed Inc484.07M

Insider trading

6 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Lyons Christopher MichaelDirectorMar 02 '26Buy2.907,53421,8498,292Mar 10 09:00 AM
Lyons Christopher MichaelDirectorFeb 25 '26Buy2.967582,244758Mar 10 09:00 AM
MOYES JAY MDirectorFeb 23 '26Buy2.911,0002,9104,000Feb 25 09:00 AM
Anderson Mark LewisDirectorFeb 18 '26Buy3.023,0009,06018,000Feb 19 09:00 AM
Honigblum Gregg R.Chief Investment OfficerDec 08 '25Buy4.268,20034,896201,067Dec 09 08:00 AM
Honigblum Gregg R.Chief Investment OfficerDec 05 '25Buy3.9365,000255,350139,000Dec 08 08:00 AM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 103
  • SINTX Technologies Advances SiN/PEEK 3D Printing Platform Toward Personalized Orthopedic Implant Commercialization (GlobeNewswire)
  • SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization (GlobeNewswire)
  • SINTX Must Prove Its Doubled Revenue Forecast Reflects Durable Demand, Not A One-Off (Earnings Whispers)
  • SINTX Technologies Announces Third Quarter 2026 Earnings Release Date and Webcast (GlobeNewswire) -5.75%
  • SINTX Announces Preliminary $2.2 Million in Q3 Revenue, Exceeding High-End Guidance (GlobeNewswire)
  • Loading…
  • SINTX Technologies Announces Silicon Nitride Masterclass with Leading Orthopedics Experts (GlobeNewswire)
  • SINTX Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire) +6.75%
  • SINTX Technologies Regains Compliance with Nasdaq Stockholders' Equity Requirement (GlobeNewswire) +8.92%
  • SINTX Technologies Inc (SINT) (Q2 2026) Earnings Call Highlights: Revenue Surges 199% as ... (GuruFocus.com) -11.30%
  • SINTX Technologies Provides Mid-Year 2026 Business Update Highlighting Commercial Execution, Biomaterial Platform Expansion and Strategic Growth Initiatives (GlobeNewswire)
  • SINTX Technologies Announces Second Quarter 2026 Earnings Release Date and Webcast (GlobeNewswire)
  • SINTX Technologies Engages Veteran MedTech Executive Chris Lyons and Southern Metrics to Establish Strategic Opportunity Management Program (GlobeNewswire)
  • SINTX Technologies Announces Receipt of More Than $3.2 Million in Contract Manufacturing Purchase Orders (GlobeNewswire) -5.69%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.240-0.307-0.2402.191.333
2026Q22026-08-11-0.750-0.730-0.7490.450.462
2026Q12026-05-15-0.700-0.660-0.7030.390.302
2025Q42026-03-30-1.445-0.550-0.5580.300.301
2025Q32025-11-13-3.460-0.550-3.4610.210.201
2025Q22025-08-14-0.910-0.790-0.9140.200.401
2025Q12025-05-16-1.290-0.755-1.2930.400.732
2024Q42025-03-24-1.330-1.400-1.2620.520.541
2024Q32024-11-18-6.950-7.200-6.9610.800.701
2024Q22024-08-15-3.160-5.310-3.6050.860.701
2024Q12024-05-10-5.140-14.000-10.2640.690.802
2023Q42024-03-28-44.000-88.000-105.010.900.901
2023Q32023-11-13-146-152-151.610.680.572
2023Q22023-08-08-134-134-121.910.500.502
2023Q12023-05-15-168-248-25.7800.520.562
2022Q42023-03-29-3,506-1,204-4,0610.780.771

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-61,600-105,800-113,7030.700.62
2020FY-10,600-20,500-21,6530.590.56
2021FY-7,600--798,1620.61-
2022FY-10,506-7,046-12,1621.581.57
2023FY-380.29-400-624.482.612.63
2024FY-14.800-14.800-15.1922.902.89
2025FY-6.160-6.060-6.1601.011.10
2026FY--1.800--3.12
2027FY--1.063--5.80
2028FY--0.570--31.30
2029FY-1.010--68.50
2030FY-1.560--95.80

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-063010.940.731.20
2026Q4S2026-10-273001.050.901.20
2026Q4S2026-10-263101.050.901.20
2026Q4S2026-09-293201.050.901.20
2026Q4S2026-08-122101.131.051.20
2026Q4S2026-08-022000.830.601.05
2026Q4S2026-07-152100.830.601.05
2026Q4S2026-06-033100.750.601.05
2026Q4S2026-05-192100.600.600.60
2026Q4S2026-05-152000.450.300.60
2026Q4S2026-04-092000.450.300.60
2026Q4S2026-04-061000.600.600.60
2026Q4S2025-12-031000.600.600.60
2026Q4S2025-11-131010.600.600.60

Estimate history

EPS, annual-1879014.008-1605402.006-113702.6-21653-798162-12161.74-624.478-15.192-6.159-2.2489
Period201720182019202020212022202320242025TTM
EPS, quarterly-6.961-1.262-1.293-0.914-3.461-0.558-0.703-0.749-0.239
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00.0950.6890.5940.6061.5612.6272.8871.0183.31
Period201720182019202020212022202320242025TTM
Sales, quarterly0.7990.5420.3690.1510.2080.290.380.4522.19
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0000.00100.0030.0271.3433.9716.887
Period201720182019202020212022202320242025MRQ
Shares, quarterly1.3431.3432.4872.4873.6163.9714.1196.6136.887
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue3.311.022.892.631.560.610.590.690.10
Cost of Goods Sold Incl. D&A1.501.222.192.441.231.100.970.550.11
Gross Profit1.81-0.200.690.190.33-0.49-0.380.14-0.02
Selling, General and Administrative Excl. Other11.7110.368.4312.4110.8110.138.126.736.94
Research and Development2.454.595.208.716.455.894.813.392.99
Other Operating Expense0.150.161.301.130.850.000.000.000.00
Operating Income-10.05-10.72-9.04-13.36-11.34-10.62-8.50-6.59-6.95
Interest Expense0.030.050.030.000.020.030.000.001.39
Unusual Expense-0.520.122.08-4.931.09-1.09-0.86-1.301.43
Net Income Before Taxes-9.34-10.36-11.02-8.26-12.04-9.31-7.03-4.80-9.69
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-9.34-10.36-11.02-8.26-12.04-9.31-7.03-4.80-9.69
Net Income From Continuing Operations-9.34-10.36-11.02-8.26-12.04-9.31-7.03-4.80-9.69
Net Income-10.26-17.08-11.02-8.29-16.49-9.31-16.59-7.50-23.91
EPS (Recurring)-1.59-6.13-13.23-782.94-11,680.40-858,863.75-22,347.05-125,426.42-1,553,207.91
EPS (Basic, Before Extraordinaries)-2.25-6.16-14.87-443.47-10,933.99-754,012.40-20,228.40-96,401.80-1,311,732.01
EPS (Diluted)-2.25-6.16-15.19-624.48-12,161.74-798,162.00-21,653.00-113,702.60-1,605,402.01
EBITDA-9.43-10.06-7.65-11.70-10.37-9.97-8.01-6.12-6.84
Non-Operating Income (Expense)0.210.530.130.170.400.250.610.500.08
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.771.390.080.290.370.310.040.000.04
Price To Sales Ratio4.4910.520.900.631.970.2746.113.3621.82
Gross Margin54.71-19.7423.977.0821.33-81.35-63.8020.03-16.32
Operating Margin-303.38-1,053.14-313.06-508.49-726.14-1,752.48-1,431.65-957.04-7,318.95
Net Margin-309.87-1,678.09-381.85-315.38-1,056.31-1,536.14-2,793.60-1,088.53-25,171.58
Shares Outstanding6.893.971.340.030.000.000.000.000.00
Market Capitalization11.7211.724.701.602.3915.8638.553.633.92

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue2.190.450.380.290.210.150.370.54
Cost of Goods Sold Incl. D&A0.830.170.240.260.270.250.440.38
Gross Profit1.360.280.140.03-0.07-0.10-0.070.16
Selling, General and Administrative Excl. Other2.943.163.302.313.272.522.271.51
Research and Development0.550.570.360.971.261.241.120.71
Other Operating Expense0.060.000.050.030.020.050.050.24
Operating Income-1.64-2.89-3.21-2.32-3.35-2.67-2.38-1.59
Interest Expense0.000.000.010.010.010.010.010.01
Unusual Expense0.00-0.14-0.34-0.040.210.04-0.090.13
Net Income Before Taxes-1.59-2.71-2.82-2.21-3.54-2.32-2.29-1.70
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-1.59-2.71-2.82-2.21-3.54-2.32-2.29-1.70
Net Income From Continuing Operations-1.59-2.71-2.82-2.21-3.54-2.32-2.29-1.70
Net Income-1.59-3.63-2.82-2.21-10.26-2.32-2.29-1.70
EPS (Recurring)-0.24-0.77-0.76-0.57-3.41-0.90-1.33-1.19
EPS (Basic, Before Extraordinaries)-0.24-0.75-0.70-0.56-3.46-0.91-1.29-1.26
EPS (Diluted)-0.24-0.75-0.70-0.56-3.46-0.91-1.29-1.26
EBITDA-1.48-2.73-3.05-2.16-3.20-2.51-2.19-1.36
Non-Operating Income (Expense)0.040.040.060.070.040.400.020.04
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.240.350.530.650.550.560.020.01
Price To Sales Ratio4.496.829.7615.069.544.391.841.63
Gross Margin62.1961.5037.899.66-31.73-63.58-18.1630.07
Operating Margin-74.66-638.94-843.95-799.31-1,612.98-1,764.90-645.80-292.80
Net Margin-72.83-803.54-742.37-763.79-4,931.73-1,535.10-621.14-312.73
Shares Outstanding6.896.614.123.973.622.492.491.34
Market Capitalization11.728.0810.3214.8711.288.086.694.70

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments4.143.603.346.2514.2725.351.795.450.54
Short Term Receivables0.180.200.690.330.101.901.861.351.24
Inventories0.820.500.890.280.300.100.110.050.12
Other Current Assets0.510.470.620.350.350.240.310.171.77
Total Current Assets5.654.775.537.2115.0327.594.067.023.67
Net Property, Plant & Equipment2.934.088.928.006.412.402.530.120.22
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Long-Term Note Receivable-----0.001.943.670.00
Intangible Assets0.440.020.020.030.030.040.040.056.16
Other Assets0.480.550.890.540.370.420.570.664.59
Total Assets9.519.4115.3715.7721.8430.459.1511.5214.64
Short Term Debt Incl. Current Port. of LT Debt0.410.490.560.901.010.510.370.000.60
Accounts Payable0.380.300.640.430.240.190.190.301.73
Other Current Liabilities2.951.201.716.751.502.171.512.085.93
Total Current Liabilities3.731.982.918.082.752.882.072.388.27
Long Term Debt2.843.543.691.991.901.761.880.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.740.93
Total Liabilities6.585.526.5910.074.644.643.943.129.20
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity2.933.898.775.7017.2025.805.208.405.44
Total Shareholders Equity2.933.898.775.7017.2025.805.208.405.44
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity2.933.898.775.7017.2025.805.208.405.44
Total Liabilities & Stockholders Equity9.519.4115.3715.7721.8430.459.1511.5214.64
Book Value Per Share0.742.90329.732,104.231,391,710.4421,019.5342,744.30231,232.591,078,312.39
Tangible Book Value Per Share0.632.89328.942,094.641,389,201.4020,990.2042,407.40229,966.16-142,863.51
Full-Time Employees322043413632281933
Price to Book Ratio3.150.840.150.250.891.490.700.470.95
Return on Assets-109.56-88.98-53.05-64.02-35.61-35.51-46.43-74.09-28.17
Return on Equity-303.80-174.07-114.11-102.76-43.30-45.34-70.54-140.00-69.09
Return on Invested Capital-179.53-148.35-66.29-156.49-48.76-25.50-67.74-119.22-171.43
Quick Ratio1.292.151.600.865.369.551.922.930.43
Current Ratio1.512.411.900.895.479.581.972.950.44

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-9.34-10.36-11.02-8.26-12.04-9.31-7.03-4.80-9.69
Depreciation0.620.661.381.660.960.650.500.470.11
Other Funds (Non Cash)1.311.851.23-5.271.46-0.98-2.04-1.751.64
Funds from Operations-7.41-7.85-8.41-11.88-9.62-9.64-8.57-6.07-7.94
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-1.57-0.72-0.23-2.24-0.65-0.48-0.54-0.36-1.41
Cash from Operating Activities-8.97-8.57-8.64-14.12-10.26-10.13-9.11-6.43-9.35
Capital Expenditures-0.28-0.18-0.69-0.53-1.41-3.74-0.36-0.15-0.06
Net Assets From Acquisitions-0.00-0.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.001.100.020.030.300.140.000.00-
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00-0.08
Other Sources0.000.000.480.000.001.942.111.530.00
Cash from Investing Activities-0.280.91-0.19-0.50-1.10-1.661.751.38-0.14
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock5.228.419.445.170.000.2030.551.5515.98
Repurchase of Common Pref Stock0.00-0.130.00-0.000.000.000.000.000.00
Sale of Common Pref Stock5.228.549.445.180.000.2030.551.5515.98
Proceedsfrom Stock Options1.200.330.000.000.000.0029.431.4514.33
Issuance or Reduction of Debt, Net-0.16-0.21-0.356.54-0.510.510.38-0.16-1.58
Change in Long Term Debt-0.16-0.21-0.356.54-0.510.510.380.000.00
Issuance of Long Term Debt0.000.000.006.650.000.510.410.000.00
Reduction of Long Term Debt-0.16-0.21-0.35-0.11-0.510.00-0.030.000.00
Net Financing Active Other Cash Flow-0.060.000.000.003.840.000.000.000.00
Other Financing Activities Uses-0.060.000.000.000.000.000.000.000.00
Cash from Financing Activities5.008.209.0911.713.340.7030.931.3914.40
Net Change in Cash-4.250.540.26-2.90-8.03-11.0823.56-3.664.91
Free Cash Flow-9.25-8.76-9.33-14.64-11.67-13.87-9.47-6.58-9.36
Preferred Dividends (Cash Flow)--0.00--0.00---
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments2.003.591.894.146.254.32
Short Term Receivables0.130.330.360.180.120.10
Inventories2.562.251.390.820.450.35
Other Current Assets0.830.850.680.510.580.78
Total Current Assets5.527.034.325.657.395.55
Net Property, Plant & Equipment2.732.732.792.933.043.11
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.420.430.430.440.450.01
Other Assets0.230.250.260.480.470.52
Total Assets8.9010.437.819.5111.369.20
Short Term Debt Incl. Current Port. of LT Debt0.490.530.530.410.440.48
Accounts Payable0.960.930.570.380.200.18
Other Current Liabilities1.551.513.072.953.701.50
Total Current Liabilities3.002.984.173.734.352.16
Long Term Debt2.512.622.732.842.953.05
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities5.515.606.916.587.305.21
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity3.394.830.902.934.073.99
Total Shareholders Equity3.394.830.902.934.073.99
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity3.394.830.902.934.073.99
Total Liabilities & Stockholders Equity8.9010.437.819.5111.369.20
Book Value Per Share0.490.730.220.741.131.60
Tangible Book Value Per Share0.430.670.110.631.001.60
Full-Time Employees---32--
Price to Book Ratio3.158.523.393.432.551.31
Return on Assets-92.14-114.97-113.12-109.56-86.86-102.44
Return on Equity-250.39-255.86-311.41-303.80-204.04-195.48
Return on Invested Capital-27.04-36.31-77.52-38.37-50.43-32.94
Quick Ratio0.991.600.701.291.602.41
Current Ratio1.842.361.041.511.702.57

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-1.59-2.71-2.82-2.21-3.54-2.32
Depreciation0.150.150.160.160.160.15
Other Funds (Non Cash)0.290.210.200.611.10-0.03
Funds from Operations-1.15-2.34-2.47-1.45-2.28-2.20
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.22-0.43-0.02-0.90-0.24-0.21
Cash from Operating Activities-1.37-2.77-2.49-2.34-2.52-2.41
Capital Expenditures-0.14-0.08-0.01-0.04-0.080.00
Net Assets From Acquisitions0.000.000.00-0.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.750.35
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.14-0.08-0.01-0.040.670.35
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)--0.00--0.00
Change in Capital Stock0.044.590.270.333.83-0.07
Repurchase of Common Pref Stock0.000.000.000.000.00-0.05
Sale of Common Pref Stock0.044.590.270.333.83-0.02
Proceedsfrom Stock Options0.060.550.270.330.00-0.09
Issuance or Reduction of Debt, Net-0.05-0.04-0.02-0.05-0.05-0.06
Change in Long Term Debt-0.05-0.04-0.02-0.05-0.05-0.06
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.05-0.04-0.02-0.05-0.05-0.06
Net Financing Active Other Cash Flow-0.060.000.000.000.000.00
Other Financing Activities Uses-0.060.000.000.000.000.00
Cash from Financing Activities-0.074.550.250.283.78-0.12
Net Change in Cash-1.581.70-2.25-2.111.93-2.18
Free Cash Flow-1.51-2.85-2.50-2.39-2.60-2.41

Revenue breakdown

Grant and Contract2024: 1.64M 2025: 289.00K
Product2024: 1.25M 2025: 729.00K
United States2024: 2.89M 2025: 1.02M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.25%0.1M5.7M114.21K
2026-10-152.25%0.1M6.1M114.66K
2026-09-301.76%0.1M5.7M99.24K
2026-09-151.71%0.1M5.7M100.96K
2026-08-312.99%0.2M5.6M113.45K
2026-08-142.39%0.1M5.6M114.98K
2026-07-312.16%0.1M5.4M48.31K
2026-07-152.86%0.2M5.4M51.16K
2026-06-303.85%0.2M4.9M50.67K
2026-06-153.77%0.1M3.3M47.68K
2026-05-295.75%0.2M3.4M35.47K
2026-05-156.20%0.2M3.4M35.32K
2026-04-306.86%0.2M3.2M33.43K
2026-04-156.17%0.2M3.2M33.04K
2026-03-317.99%0.3M3.2M34.57K
2026-03-136.62%0.2M3.2M35.96K
2026-02-277.46%0.2M3.0M52.18K
2026-02-136.82%0.2M3.0M56.16K
2026-01-306.22%0.2M3.0M61.36K
2026-01-156.28%0.2M3.0M177.53K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-058-KCurrent report2026-11-05SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-30DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-30SEC
2026-10-098-KCurrent report2026-10-08SEC
2026-10-018-KCurrent report2026-10-01SEC
2026-08-18EFFECTEffectiveness filing by commission orderSEC
2026-08-138-KCurrent report2026-08-12SEC
2026-08-13S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-08-13SCHEDULE 13GSEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-238-KCurrent report2026-07-23SEC
2026-07-028-KCurrent report2026-06-29SEC
2026-06-25S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-06-09SCHEDULE 13GSEC
2026-06-09SCHEDULE 13GSEC
2026-06-038-KCurrent report2026-06-02SEC
2026-05-278-KCurrent report2026-05-22SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-144Statement of changes in beneficial ownership of securities2026-04-13SEC
2026-03-2010-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-184Statement of changes in beneficial ownership of securities2026-03-16SEC
2026-03-104Statement of changes in beneficial ownership of securities2026-02-23SEC
2026-02-254Statement of changes in beneficial ownership of securities2026-02-23SEC
2026-02-194Statement of changes in beneficial ownership of securities2026-02-18SEC
2026-02-188-KCurrent report2026-02-18SEC
2026-02-104Statement of changes in beneficial ownership of securities2026-02-06SEC
2026-02-104Statement of changes in beneficial ownership of securities2026-02-06SEC
2026-02-104Statement of changes in beneficial ownership of securities2026-02-06SEC
2025-12-11EFFECTEffectiveness filing by commission orderSEC
2025-12-09CORRESPSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-0321.85K100
2026-0214.21K300
2026-010000
2025-12290.25K200
2025-1131.90K100

Institutional holders

Manager% owned
Bleichroeder LP12.11%
Stonepine Capital Management, LLC4.84%
Veracity Capital LLC1.15%
CITADEL ADVISORS LLC0.74%
VANGUARD FIDUCIARY TRUST CO0.54%
VANGUARD CAPITAL MANAGEMENT LLC0.48%
GEODE CAPITAL MANAGEMENT, LLC0.38%
STATE STREET CORP0.31%
HRT FINANCIAL LP0.30%
Virtus Wealth Solutions LLC0.15%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.48%
Fidelity Extended Market Index Fund0.25%
Fidelity Series Total Market Index Fund0.06%
Fidelity Total Market Index Fund0.03%
Dimensional U.S. Core Equity 2 ETF0.02%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. SINT. Cached 15 minutes.